Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Toficalm

Toficalm
In stock
50mg
from A$41.55
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$49.86A$41.55
A$4.16 per tablet

In brief

  • In many pharmacies (notably in India) and through some online sellers toficalm can be purchased without a prescription; however, in regulated markets (including parts of Europe and Australia) it is generally prescription‑only.
  • Toficalm (tofisopam) is used as an anxiolytic and adjunct in certain depressive states and alcohol‑withdrawal management; it is a 2,3‑benzodiazepine derivative that produces anxiolysis via modulation of GABAergic and related central pathways in a manner distinct from classical 1,4‑benzodiazepines (exact mechanism not fully understood).
  • Usual adult doses are 50–100 mg taken 2–3 times daily (individual dosing and frequency should be guided by a clinician and adjusted for elderly or those with hepatic/renal impairment).
  • Administration is oral tablet; commonly available strengths are 50 mg and 100 mg tablets, swallowed with water.
  • Onset of effect is typically within 30–60 minutes for anxiolytic benefit.
  • Duration of action is generally around 4–6 hours, with individual variation.
  • Do not consume alcohol while taking toficalm; alcohol and acute intoxication are contraindicated and increase risk of adverse effects.
  • The most common side effect is drowsiness (other frequent effects include nausea/dry mouth, dizziness, headache and fatigue).
  • Would you like to try toficalm without a prescription?

Critical Warnings & Restrictions — Patient Protection First

Basic Toficalm Information

  • INN (International Nonproprietary Name): Tofisopam
  • Brand Names Available In Australia: not specified
  • ATC Code: N05BA23
  • Forms & Dosages: Tablet; strengths 50 mg and 100 mg; common packaging blisters/boxes (10×10 tablets)
  • Manufacturers In Australia: not specified
  • Registration Status In Australia: not specified
  • OTC / Rx Classification: Prescription Only (Rx)

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Who should we screen carefully before starting toficalm?

Patients older than 65 years, anyone who is pregnant or breastfeeding, and people with severe hepatic or respiratory disease need special attention.

Sleep apnoea and a history of substance dependence represent important absolute or relative risks for harm with tofisopam use.

Regulatory data list severe hepatic impairment, respiratory insufficiency, sleep apnoea and acute intoxication as absolute contraindications for tofisopam.

Start elderly patients at the lowest effective dose and monitor closely for drowsiness, falls and cognitive effects.

Patients with chronic respiratory disease should be assessed for baseline respiratory function before treatment, where clinically appropriate.

  • Use this checklist for pre‑treatment screening:
  • Medical history including liver and lung disease, sleep apnoea, psychiatric diagnoses and substance use.
  • Current medications and over‑the‑counter products that depress the central nervous system.
  • Alcohol use screening and recent intoxication history.
  • Pregnancy test for women of childbearing potential, and discussion about breastfeeding.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Drowsiness is one of the most common adverse effects of tofisopam.

Refrain from driving or operating heavy machinery until the individual response to the medicine is known.

Australian road safety laws treat impairment from prescribed drugs similarly to impairment from alcohol when it affects driving performance.

Employees in safety‑critical roles must be counselled about potential impairment and may need to notify their employer according to workplace policy.

  • Workplace safety actions: temporarily restrict safety‑critical duties until tolerance is established.
  • Advise supervisors where occupational health rules require disclosure for safety roles.
  • Recommend staggered return to high‑risk tasks with clinical clearance if sedation persists.
  • Document counselling in the patient record and provide written advice about impairment risks.

Q&A — “Can I Drive After Taking It In Australia?”

Q: Short answer — avoid driving if drowsy.

Australian law treats impairment from prescribed drugs like alcohol for road safety; if you feel sedated do not drive and seek advice from your prescriber or pharmacist.

Quick‑check checklist for fitness to drive:

  • Rate your sleepiness on a simple 1–10 scale; avoid driving if above 4 and feeling slowed reactions.
  • Note any complaints of slowed reaction time or difficulty focusing after the dose.
  • Check for co‑medications that increase sedation such as opioids, benzodiazepines or certain antipsychotics.

Usage Basics

INN And Brand Names (Relevance To Australia)

INN: Tofisopam.

Global brands include Toficalm, Grandaxin, Tofisign, Tofiso, TOFIZIN, Nextril and Emandaxin.

Several Indian and European manufacturers supply 50 mg and 100 mg tablets.

Brand Country/Region Strengths Manufacturer/Supplier
Toficalm India 50 mg, 100 mg Torrent Pharmaceuticals; Apple Pharma
Grandaxin Europe, Russia, Turkey 50 mg, 100 mg Egis, others
Tofisign India 100 mg A M Overseas
Tofiso India 50 mg Apple Pharmaceuticals
Emandaxin Europe 50 mg, 100 mg Local/various

Legal Classification (TGA Approval, PBS Listing)

Tofisopam is classified as prescription‑only (Rx) in regulated markets.

Approvals exist in India and parts of Europe; it is not approved in the United States or Canada.

For Australia, always check the TGA ARTG and PBS lists before prescribing or importing; do not assume local registration.

  • Verification steps for pharmacists:
  • Search the TGA ARTG for “tofisopam” and known brand names.
  • Check the PBS for any subsidy code or listing.
  • Contact the product sponsor or supplier for registration details if necessary.

Dosing Guide

Standard Regimens (PBS Reference Dosing Approach)

Typical adult dosing from global product information is 50–100 mg taken two to three times daily for anxiety.

Similar regimens are reported for adjunctive use in depression and for alcohol‑withdrawal support (off‑label).

Aim for the lowest effective dose and a short duration of therapy, typically two to six weeks for anxiety.

Indication Typical Dose Frequency
Anxiety 50–100 mg Two to three times daily
Adjunctive Depression 50–100 mg Two to three times daily
Alcohol Withdrawal (Off‑Label) 50–100 mg Two to three times daily

Dosing checklist for initiation:

  • Confirm indication and prior response to anxiolytics.
  • Check for contraindications and relevant comorbidities.
  • Start at the lower end of the dose range and schedule a follow‑up in 1–2 weeks.

Adjustments For Comorbidities

Reduce dose or increase dosing interval for elderly patients and for those with hepatic or renal impairment.

Combine tofisopam cautiously with other CNS depressants and consider dose reductions when co‑prescribing opioids or benzodiazepines.

Children: use is not generally recommended due to lack of established safety and efficacy data.

Q&A — “What If I Miss A Dose?”

Q: Take the missed dose as soon as you remember unless it is near the time of the next scheduled dose.

Do not double up doses to make up for a missed one.

If it is close to the next dose, skip the missed dose and resume the regular schedule.

Provide a simple missed‑dose flowchart in the patient leaflet: miss → take if more than half the interval left → otherwise skip.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Alcohol is an important hazard with tofisopam; acute intoxication is a contraindication to starting treatment.

Alcohol increases sedation and the risk of respiratory depression when taken with tofisopam.

Caffeine may temporarily mask sedation but will not prevent impairment of reaction time or respiratory drive.

  • Avoid alcohol while taking tofisopam.
  • Moderate caffeine intake; be cautious with energy drinks that may worsen anxiety.
  • Advise patients that alcohol and sedating drugs together increase risk of accidents and overdose.

Common Drug Conflicts

High‑risk co‑medications include opioids, other benzodiazepines and thienodiazepines, sedating antipsychotics and some first‑generation antihistamines.

Strong cytochrome P450 inhibitors or inducers may alter plasma levels where metabolism is relevant; monitor and adjust doses as required.

Interacting Drug Class Expected Effect Monitoring / Action
Opioids Increased sedation and respiratory depression Avoid combination where possible; if necessary, reduce doses and monitor closely
Benzodiazepines / Thienodiazepines Additive sedation and motor impairment Avoid co‑prescribing; counsel on falls risk and driving
Antipsychotics Increased CNS depression Monitor sedation and orthostatic symptoms; consider dose adjustments
Antihistamines (sedating) Increased drowsiness and cognitive impairment Advise avoidance or substitution with non‑sedating alternatives

Pharmacist checklist at dispensing:

  • Review current medicines for CNS depressant combinations.
  • Consider dose reduction and provide targeted counselling on sedation and falls prevention.
  • Schedule early follow‑up and advise when to seek urgent care for respiratory symptoms.

User Reports & Trends (Australian Patient Feedback)

What Australians talk about online when searching for toficalm?

Common search phrases include “Toficalm 100 mg”, “Tofisopam side effects”, “Toficalm price” and “Toficalm buy online India”.

Typical patient notes on forums and review sites mention anxiolytic benefit with reportedly less sedation than diazepam.

Some users report nausea, dizziness or headache; availability and price are frequent concerns.

Keep selection bias in mind when reading forums; people who have a problem are more likely to post.

  • Data sources to mine for sentiment analysis: ProductReview, patient forums, local Facebook groups, pharmacy counselling notes.
  • Template table for sentiment analysis: efficacy | side effects | access | price.

Combine patient feedback with pharmacist‑reported adverse reactions and TGA databases for a balanced view.

Access & Purchase Options (Australia)

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

If tofisopam is TGA‑listed and stocked, major pharmacy chains may dispense it; otherwise supply may be through hospital pharmacies, private imports or specialist clinics.

It is prescription only — photographic ID and a valid prescription are required for dispensing when registered locally.

  • Checklist for community pharmacists: verify ARTG entry, confirm supplier details, and avoid substitution without prescriber approval.
  • Where supply is via private import, ensure quality assurance and documentation.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth e‑prescriptions are common in Australia but pharmacists must verify ARTG and PBS status before dispensing or arranging supply.

Personal importation schemes exist but require careful adherence to TGA rules and acceptance of regulatory risk.

In our online pharmacy, toficalm is available without a prescription, with discreet delivery to Australia in 9-21 days.

Access Route Pros Cons / Legal Notes
Community Pharmacy Immediate counselling, local supply if registered Requires ARTG registration and valid prescription
Australian Online Pharmacy Convenience, telehealth integration Verify ARTG/PBS; ensure sponsor details
International Import Access when not locally registered Regulatory risk; quality and supply chain concerns

Mechanism & Pharmacology

Simplified Explanation

Tofisopam is a 2,3‑benzodiazepine derivative, distinct from classical 1,4‑benzodiazepines.

It is classified under ATC code N05BA23 as an anxiolytic.

Clinically it provides anxiolysis with reportedly less sedation and muscle relaxation than classic benzodiazepines.

Clinical Terms (PK/PD Summary)

Expect a relatively rapid onset of anxiolytic effect when dosed two to three times daily, although exact onset and half‑life vary by formulation and individual metabolism.

Metabolism details and precise pharmacokinetics should be confirmed from the product monograph for each brand and formulation.

Although less likely to cause marked cognitive or motor impairment, dependence with prolonged use remains a recognised risk.

  • Definitions for patient handouts: INN, ATC, chemical class, pharmacological highlights.

Indications & Off‑Label Uses

Approved Indications By Regulatory Authorities

Regulatory approvals for tofisopam exist in India and parts of Europe for use as an anxiolytic.

For Australia, confirm TGA registration status before prescribing or dispensing; local approval is not assumed.

Off‑Label Uses In Clinical Practice (Documented)

Documented off‑label uses include adjunctive treatment for depression and adjunctive use in alcohol‑withdrawal management at doses of 50–100 mg two to three times daily.

Off‑label prescribing must be justified, documented and discussed with the patient, including consent and monitoring plans.

  • Off‑label prescribing checklist: evidence summary, alternative treatments, informed consent, monitoring schedule.

Key Clinical Findings (Evidence Summary)

Clinical literature, mainly from European and Indian trials and observational studies, suggests tofisopam reduces anxiety with comparatively less sedation and motor impairment than typical benzodiazepines.

Dependency risk remains with prolonged therapy and short‑term use is advised where appropriate.

No large Australian randomised controlled trial data are highlighted in the source product information; check PubMed and Cochrane for the most recent RCTs and meta‑analyses.

Evidence Level Typical Findings
Randomised Trials Show anxiolytic effect versus placebo or active comparators in some populations
Observational Studies Support lower sedation and preserved motor function compared with classic benzodiazepines
Case Reports Document individual adverse events and off‑label outcomes

Suggested literature search checklist: keywords (tofisopam, Grandaxin, toficalm, anxiolytic), databases (PubMed, Cochrane, Embase), and date range filters up to 2026.

Extract for each study: population, dose, comparator, outcomes and adverse events.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Drug Class Onset Sedation Risk Dependence Potential PBS Listing Typical Cost
Diazepam 1,4‑benzodiazepine Fast High High Often PBS‑listed Varies
Oxazepam 1,4‑benzodiazepine Moderate Moderate Moderate Often PBS‑listed Varies
Alprazolam 1,4‑benzodiazepine Fast High High Usually PBS‑restricted Varies
Buspirone Non‑benzodiazepine anxiolytic Slower onset (days) Low Low Varies Varies

Pros And Cons Checklist

  • Diazepam: pros — rapid onset; cons — high sedation and dependence risk; consider PBS status and patient history.
  • Oxazepam: pros — useful in elderly with hepatic considerations; cons — still sedating.
  • Alprazolam: pros — effective for acute anxiety; cons — high dependence potential and strict regulation.
  • Buspirone: pros — lower sedation and dependence; cons — slower onset and may not help acute panic.

Decision checklist for clinicians: review indication, patient risk factors, PBS access and prior medication responses before choosing an alternative.

Common Questions — Quick Pharmacy FAQ (Australian Focus)

Can I breastfeed while taking toficalm?

Breastfeeding is not recommended unless the prescriber and a specialist judge the benefit justifies the risk; consult product monograph and specialist advice.

What about pregnancy?

Avoid use in pregnancy unless absolutely necessary and after consultation with an obstetrician; consider alternative therapies first.

Is there dependence risk?

Yes; short‑term use (two to six weeks) is recommended and tapering should be used after prolonged therapy to reduce withdrawal risk.

Can I mix toficalm with alcohol?

No — mixing with alcohol is contraindicated due to increased sedation and respiratory depression risk.

  • Patient counselling checklist: provide clear written information, driving and alcohol warnings, and when to seek urgent care (respiratory depression, severe confusion).
  • Escalation triggers: suicidality, severe ADRs, pronounced respiratory symptoms.

Price & Access Comparison Table (Practical Build)

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Supplier Brand Strength Pack Size Typical Price (AUD Estimate) PBS Status Notes
Community Pharmacy Depends on local stock 50 mg / 100 mg 10×10 Not specified Unspecified (check PBS) ARTG verification required
Australian Online Pharmacy Imported brands 50 mg / 100 mg 10×10 Not specified Unspecified Check quality and sponsor details
International Import Toficalm, Grandaxin, others 50 mg / 100 mg Varies Not specified Not subsidised Regulatory and quality risks

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Check ARTG before ordering; contact supplier for batch and quality information if not locally registered.
  • Rural considerations: allow for telehealth prescriptions, courier delays and storage concerns during transit.
  • Safe procurement checklist: ARTG verification, quality assurance certificates, batch numbers and expiry checks on receipt.

Registration & Regulation (TGA & PBS Practical Steps)

TGA Approval Process And ARTG Checks

Search the TGA ARTG for “tofisopam” or known brand names to confirm registration status and sponsor details.

If a product is unregistered in Australia, determine legal import routes such as the Special Access Scheme or an authorised prescriber pathway.

PBS Subsidy Details & Pharmacovigilance

PBS listing determines cost to the patient; source data does not indicate a PBS listing for tofisopam and it is likely unsubsidised unless subsequently listed.

Report suspected adverse drug reactions to the TGA via usual reporting channels and maintain local pharmacovigilance logs.

  • Stepwise checklist when the drug is not TGA‑registered: consider SAS application, obtain informed consent, document reasons and monitoring plans.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store below 25°C and protect from moisture.

Keep tablets in their original blister until use to limit humidity exposure.

Avoid storage in bathrooms, gloveboxes or cars where temperatures and humidity can exceed recommended limits.

Cold‑Chain Handling For Pharmacies

Although tofisopam is not a cold‑chain product, maintain climate‑controlled transport to avoid degradation in hot or humid conditions.

Inspect blister integrity and packaging on receipt and log storage temperatures in the dispensary.

  • Dispensing staff checklist: storage temperature logs, expiry date checks, intact blister verification and safe disposal advice for patients.
  • Patient handout: keep away from children, do not share medication, return unused medicines to a pharmacy for disposal.

Guidelines For Proper Use — Pharmacist Counselling & Patient Monitoring

Australian Pharmacist Counselling Style (Practical Points)

Explain the indication and the expected benefits clearly in plain language.

Describe the dose schedule and what to expect in the first one to two weeks.

Highlight likely side effects such as drowsiness, nausea, dizziness, headache and fatigue.

Give explicit driving and alcohol warnings and discuss workplace implications for safety‑critical roles.

Advise on treatment duration (typically two to six weeks) and the need for follow‑up.

Patient Advice Referencing PBS And National Health Authorities

Encourage follow‑up with the prescriber for reassessment and provide written information to keep with the medication.

If an imported product is used, verify batch details and quality, and document informed consent for off‑label or unregistered use.

  • Patient counselling checklist: medication purpose, dosing times, side effects to expect, missed dose advice, storage instructions and when to seek urgent care.
  • Follow‑up schedule template: phone check at 48–72 hours for tolerability, clinic or telehealth review at 1–2 weeks for efficacy and safety.

Delivery Across Australia

City Region Delivery time
Sydney New South Wales 9–14 days
Melbourne Victoria 9–14 days
Brisbane Queensland 9–14 days
Perth Western Australia 9–14 days
Adelaide South Australia 9–14 days
Hobart Tasmania 9–14 days
Darwin Northern Territory 9–14 days
Canberra Australian Capital Territory 9–14 days
Gold Coast Queensland 9–14 days
Newcastle New South Wales 9–14 days
Wollongong New South Wales 9–14 days
Geelong Victoria 9–14 days
Townsville Queensland 14–21 days
Cairns Queensland 14–21 days
Bendigo Victoria 14–21 days

Related products